Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
It often costs time, because the resulting nausea and vomiting can be severe enough to put the entire protocol on hold for weeks
What was once available only to people with excellent insurance or substantial disposable income becomes accessible to a much broader population who can benefit from effective weight loss treatment
Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
The Phase 2 trial (338 adults, 48 weeks) was published in the New England Journal of Medicine
524,525 Pancreatic cancer Researchers first compared the expression of GLP-1R in human pancreatic cancer tissues with adjacent non-tumorous pancreatic tissues, finding generally lower or absent expression of GLP-1R in pancreatic cancer tissues
This doesnt necessarily mean GLP-1s are bad, but there is a chance that future safety concerns will surface
